Genmab

www.genmab.com

PO Box 9068
Copenhagen K
1260
Denmark

+45 70 20 27 28

Activities

Ingredients | Research & Development

Related Companies

Related Content

ImaginAb announces supply agreement with Genmab
ImaginAb announces supply agreement with Genmab
Genmab and Synaffix enter into ADC license agreement
Genmab and Synaffix enter into ADC license agreement
Genmab chooses Ibex to take gene candidates to IND in 12 months
Genmab chooses Ibex to take gene candidates to IND in 12 months
Personalised cancer treatment 2.0: new combination strategy developed
Personalised cancer treatment 2.0: new combination strategy developed
Tisotumab Vedotin co-developed by Genmab and Seattle Genetics
Tisotumab Vedotin co-developed by Genmab and Seattle Genetics
Genmab appoints new CDO
Genmab appoints new CDO
Genmab enters licensing agreement with Gilead for DuoBody technology
Genmab enters licensing agreement with Gilead for DuoBody technology
Novo Nordisk pays US$2m for access to Genmab technology
Novo Nordisk pays US$2m for access to Genmab technology
Genmab teams up with BioNTech in immuno-oncology development and commercialisation agreement
Genmab teams up with BioNTech in immuno-oncology development and commercialisation agreement
Multiple myeloma – daratumumab
Multiple myeloma – daratumumab
Seattle Genetics and Genmab enter into new antibody-drug conjugate collaboration
Seattle Genetics and Genmab enter into new antibody-drug conjugate collaboration
Genmab unveils novel platform to enhance antibody therapeutics
Genmab unveils novel platform to enhance antibody therapeutics
Genmab licenses HuMax-IL8 to Cormorant Pharmaceuticals
Genmab licenses HuMax-IL8 to Cormorant Pharmaceuticals
Genmab says GSK has settled patent case with Genentech
Genmab says GSK has settled patent case with Genentech
Lonza signs antibody agreement with Genmab
Lonza signs antibody agreement with Genmab